Catridecacog

Evidence Level: L5

Predicted Indications: 3

Catridecacog

Pharmacist Assessment Report

Catridecacog: From Factor XIII A-Subunit Deficiency to Primary Release Disorder of Platelets

One-Sentence Summary

Catridecacog is a recombinant factor XIII A-subunit, originally used to treat congenital factor XIII A-subunit deficiency. The TxGNN model predicts it may be effective for primary release disorder of platelets, but no clinical trials and no publications were found to support this prediction. It rests on computational prediction alone.

Quick Overview

Item	Content
Original Indication	Factor XIII A-subunit deficiency
Predicted New Indication	Primary release disorder of platelets
TxGNN Prediction Score	0.9929
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs: 1 of 1)
Number of DINs	1 (marketed: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known information, catridecacog is a recombinant factor XIII A-subunit. Factor XIII cross-links fibrin and stabilizes the blood clot, and its replacement is established for factor XIII A-subunit deficiency.

Platelet release (secretion) disorders impair primary haemostasis through defective granule release. The link to factor XIII A-subunit replacement is therefore indirect. Better clot stability might partly offset a platelet-function defect, but it would not correct the underlying secretion abnormality.

The high TxGNN score (0.9929) is a computational prediction only. Two other predictions scored similarly and share the same weakness:

Pseudo-von Willebrand disease (score 0.9929): This is caused by a gain-of-function defect in platelet GPIbα that increases binding to von Willebrand factor. Factor XIII-A acts downstream on fibrin cross-linking and does not address this interaction. Any benefit would be nonspecific clot stabilization.
Glanzmann thrombasthenia (score 0.9915): This is caused by deficiency or dysfunction of integrin αIIbβ3, which blocks platelet aggregation. Factor XIII-A could in theory make clots firmer, but fibrinogen-dependent platelet aggregation would remain defective. Standard care is platelet transfusion, recombinant factor VIIa and antifibrinolytics. The biological rationale for catridecacog is weak.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02389975	TRETTEN	Not specified	Not specified

Safety Considerations

Please refer to the package insert for safety information. No drug-interaction records were found for catridecacog in the data compiled for this report.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction has no clinical trial or literature support (Evidence Level L5). The mechanistic link is indirect, because factor XIII A-subunit replacement does not correct the underlying platelet defect. Safety data from the Canadian label are also missing.

To proceed, the following is needed:

Health Canada package insert (warnings, contraindications), to enable safety screening. This is currently a blocking gap.
Mechanism of action data from DrugBank, to support a proper mechanistic analysis.
Preclinical or mechanistic studies showing that factor XIII A-subunit replacement improves clot stability in platelet release disorders.
A literature and trial search for the other two predicted indications (pseudo-von Willebrand disease and Glanzmann thrombasthenia) before prioritizing among the three.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.